Researchers published CHANGE‑seq‑BE in Nature Biotechnology, a tailored genome‑wide assay that sensitively and unbiasedly profiles off‑target activity induced by base editors. The method identifies low‑frequency, off‑target deaminations across genomic contexts, allowing systematic comparison of editor variants and guide designs. The paper includes benchmarking against existing assays and demonstrates that CHANGE‑seq‑BE can reveal cryptic off‑target sites missed by targeted approaches. Developers of base‑editing therapeutics can use this tool to de‑risk candidate editors before translational studies and to inform guide RNA engineering and safety assessments.